BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28478695)

  • 1. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vector-mediated gene therapy.
    Jung SC; Park ES; Choi EN; Kim CH; Kim SJ; Jin DK
    Mol Cells; 2010 Jul; 30(1):13-8. PubMed ID: 20652491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic Recovery in MPS I and MPS II Mice by AAV9-Mediated Gene Transfer to the CNS After the Development of Cognitive Dysfunction.
    Podetz-Pedersen KM; Laoharawee K; Singh S; Nguyen TT; Smith MC; Temme A; Kozarsky K; McIvor RS; Belur LR
    Hum Gene Ther; 2023 Jan; 34(1-2):8-18. PubMed ID: 36541357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic correction and cross-correction of mucopolysaccharidosis type II (Hunter syndrome) by retroviral-mediated gene transfer and expression of human iduronate-2-sulfatase.
    Braun SE; Aronovich EL; Anderson RA; Crotty PL; McIvor RS; Whitley CB
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11830-4. PubMed ID: 8265633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
    Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of an immunodeficient mouse model of mucopolysaccharidosis type II.
    Smith MC; Belur LR; Karlen AD; Podetz-Pedersen K; Erlanson O; Laoharawee K; Furcich J; Lund TC; You Y; Seelig D; Webber BR; McIvor RS
    Mol Genet Metab; 2023 Apr; 138(4):107539. PubMed ID: 37023503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II.
    Das S; Rruga F; Montepeloso A; Dimartino A; Spadini S; Corre G; Patel J; Cavalca E; Ferro F; Gatti A; Milazzo R; Galy A; Politi LS; Rizzardi GP; Vallanti G; Poletti V; Biffi A
    Mol Ther; 2024 Mar; 32(3):619-636. PubMed ID: 38310355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical studies of lymphocyte gene therapy for mild Hunter syndrome (mucopolysaccharidosis type II).
    Braun SE; Pan D; Aronovich EL; Jonsson JJ; McIvor RS; Whitley CB
    Hum Gene Ther; 1996 Feb; 7(3):283-90. PubMed ID: 8835216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Supercharged Cells" for delivery of recombinant human iduronate-2-sulfatase.
    Pan D; Jonsson JJ; Braun SE; McIvor RS; Whitley CB
    Mol Genet Metab; 2000 Jul; 70(3):170-8. PubMed ID: 10924271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage.
    Catalano F; Vlaar EC; Dammou Z; Katsavelis D; Huizer TF; Zundo G; Hoogeveen-Westerveld M; Oussoren E; van den Hout HJMP; Schaaf G; Pike-Overzet K; Staal FJT; van der Ploeg AT; Pijnappel WWMP
    Hum Gene Ther; 2024 Apr; 35(7-8):256-268. PubMed ID: 38085235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined ultrafiltration-transduction in a hollow-fiber bioreactor facilitates retrovirus-mediated gene transfer into peripheral blood lymphocytes from patients with mucopolysaccharidosis type II.
    Pan D; Shankar R; Stroncek DF; Whitley CB
    Hum Gene Ther; 1999 Nov; 10(17):2799-810. PubMed ID: 10584926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro correction of iduronate-2-sulfatase deficiency by adenovirus-mediated gene transfer.
    Di Francesco C; Cracco C; Tomanin R; Picci L; Ventura L; Zacchello E; Di Natale P; Anson DS; Hopwood JJ; Graham FL; Scarpa M
    Gene Ther; 1997 May; 4(5):442-8. PubMed ID: 9274721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
    Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA
    Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A close-up view of the Hunter syndrome.
    Ramírez CC; Alméciga-Díaz CJ; Martín-Rufián M; Cárdenas-García C; Espejo-Mojica AJ; Lobo C; Benincore EP
    Biochem Biophys Res Commun; 2024 Feb; 696():149490. PubMed ID: 38241811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II).
    Whitley CB; McIvor RS; Aronovich EL; Berry SA; Blazar BR; Burger SR; Kersey JH; King RA; Faras AJ; Latchaw RE; McCullough J; Pan D; Ramsay NK; Stroncek DF
    Hum Gene Ther; 1996 Mar; 7(4):537-49. PubMed ID: 8800749
    [No Abstract]   [Full Text] [Related]  

  • 16. Establishment of the Effectiveness of Early Versus Late Stem Cell Gene Therapy in Mucopolysaccharidosis II for Treating Central Versus Peripheral Disease.
    Mandolfo O; Liao A; Singh E; O'leary C; Holley RJ; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):243-255. PubMed ID: 37427450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
    Horgan C; Jones SA; Bigger BW; Wynn R
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II.
    Chkioua L; Khedhiri S; Ferchichi S; Tcheng R; Chahed H; Froissart R; Vianey-Saban C; Laradi S; Miled A
    Diagn Pathol; 2011 May; 6():42. PubMed ID: 21605424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome).
    Li P; Bellows AB; Thompson JN
    J Med Genet; 1999 Jan; 36(1):21-7. PubMed ID: 9950361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice.
    Smith MC; Belur LR; Karlen AD; Erlanson O; Furcich J; Lund TC; Seelig D; Kitto KF; Fairbanks CA; Kim KH; Buss N; McIvor RS
    Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101201. PubMed ID: 38374962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.